Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS. Journal of neuroinflammation, 1:106, BioMed Central, 2023. [PUMA: mult oa ubs_10004 ubs_10021 ubs_20006 ubs_20018 ubs_30063 ubs_30162 ubs_40093 ubs_40096 unibibliografie wos]
Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF. Nature immunology, (24)3:474-486, Springer, 2023. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma. Molecules, (26)24:7582, MDPI, 2021. [PUMA: mult oa ubs_10003 ubs_10004 ubs_10021 ubs_20003 ubs_20006 ubs_20018 ubs_30063 ubs_30162 ubs_30187 ubs_40093 ubs_40096 ubs_40354 unibibliografie wos]
Fc-based Duokines : dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). OncoImmunology, (11)1:2028961, Taylor & Francis, 2022. [PUMA: mult oa ubs_10004 ubs_10021 ubs_20006 ubs_20018 ubs_30063 ubs_30162 ubs_40093 ubs_40096 unibibliografie wos]
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. Journal for ImmunoTherapy of Cancer, (9)11:e003616, BioMed Central, 2021. [PUMA: mult oa ubs_10004 ubs_10021 ubs_20006 ubs_20018 ubs_30063 ubs_30162 ubs_40093 ubs_40096 unibibliografie wos]
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3. mAbs, (13)1:1902034, Taylor & Francis, 2021. [PUMA: mult oa ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40095 ubs_40096 unibibliografie wos]
A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Scientific reports, (11):13880, Springer Nature, 2021. [PUMA: dfg f2021 mult oa oafonds ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie]
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3. Molecular Cancer Therapeutics, (19)7:1474-1485, American Association for Cancer Research, 2020. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40095 ubs_40096 unibibliografie wos]
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clinical Cancer Research, (26)13:3420-3430, American Association for Cancer Research, 2020. [PUMA: mult ubs_10004 ubs_20006 ubs_20018 ubs_30063 ubs_30162 ubs_40093 ubs_40096 unibibliografie wos]
Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. mAbs, (11)1:166-177, Taylor & Francis, 2019. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. mAbs, (11)4:653-665, Taylor & Francis, 2019. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism. Cell Death and Differentiation, (27):2417–2432, Nature Publishing Group, 2020. [PUMA: mult oa ubs_10004 ubs_10021 ubs_20006 ubs_20018 ubs_20019 ubs_30063 ubs_30162 ubs_30165 ubs_40093 ubs_40096 unibibliografie wos]
Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein. Frontiers in Pharmacology, (10):1490, Frontiers Media, 2019. [PUMA: dfg f2019 mult oa oafonds ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie]
Superior Properties of Fc-comprising scTRAIL Fusion Proteins. Molecular cancer therapeutics, (16)12:2792-2802, American Association for Cancer Research, 2017. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. mAbs, (8)5:879-891, Taylor & Francis, 2016. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. mAbs, (8)1:120-128, Taylor & Francis, 2016. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis. Arthritis & rheumatology, (70)5:722-735, Wiley, 2018. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments. Abstract Book of the 43rd ESMO Congress (ESMO 2018), 29, Suppl. 8:414, Oxford Univ. Press, Elsevier, 2018. [PUMA: mult ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein. Frontiers in immunology, (8):536, Frontiers Media, 2017. [PUMA: mult oa ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]
Systemic network analysis identifies XIAP and I kappa B alpha as potential drug targets in TRAIL resistant BRAF mutated melanoma. NPJ systems biology and applications, (4):39, Nature Publishing Group, 2018. [PUMA: mult oa ubs_10004 ubs_20006 ubs_30063 ubs_40093 ubs_40096 unibibliografie wos]